Syndax Pharmaceuticals Inc (SNDX)

[dinogreeves]

SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.

[dinogreeves]

Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.

[dealerschool2006]

Nice rebound today for $SNDX, beat the street and conference call was successful!!!

[dealerschool2006]

SNDX recovering from panic sale!!!

[dealerschool2006]

Panic sale for SNDX on positive results...May options wide swings...

[DaytraderJohn]

Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

They have no product revenue.

I expect shares to be diluted after earnings.

Read their 10k. I guess it's a gamble play incase one day they do get approval.

[BoilerRoom]

$SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks

[ClayTrader]

* * $SNDX Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

[BoilerRoom]

$SNDX next week is going to be fun

[BoilerRoom]

$SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday

[BoilerRoom]

$SNDX holding this baby!

[BoilerRoom]

$SNDX keep climbing baby! Going be going up all next week

[BoilerRoom]

$SNDX looking awesome from my call at $8.00

[BoilerRoom]

$SNDX got us a runner folks!!!

[BoilerRoom]

$SNDX Chomp Chomp Chomp!

[BoilerRoom]

$SNDX Weeeeeeeeeee

[BoilerRoom]

Going to run folks.

[BoilerRoom]

$SNDX in at $8.00

[TheFinalCD]

News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...

[whytestocks]

News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html

[DewDiligence]

SNDX 3Q18 results—cash=$89.6M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html

[Spartak]

Well, the company is done. What a disaster.

[DewDiligence]

SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.

[DewDiligence]

SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.

[DewDiligence]

SNDX upgrades BoD:

https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html

[DewDiligence]

#msg-143766395

[DewDiligence]

SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html

[DewDiligence]

#msg-143642544

[DewDiligence]

SNDX 2Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html

[DewDiligence]

SNDX 2Q18 items—6/30/18 cash=$98.4M…

PR:
http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

CC slides:
http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153

[Spartak]

When does pounding stop? Someone hummers it pretty badly.

[fsantes]

Ill keep a look out for some then!... I’ve been looking as well. Thank you!

[DewDiligence]

No. I generally post anything that's material.

[fsantes]

Have you heard any new news on SNDX?

[fsantes]

I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it

[DewDiligence]

SNDX requested that the SEC keep this document in redacted form:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

This was filed as an exhibit to the most recent 10-Q.

[fsantes]

Do you know what’s the news that came out about? When I look it’s blank..

[DewDiligence]

SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.

[DewDiligence]

SNDX ENCORE-601 update…

PR:
https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

CC slides:
http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f

[tika1]

After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.

[DewDiligence]

Transcript of SNDX 1Q18 CC:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html

[DewDiligence]

SNDX new investor slide set:

http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0

[DewDiligence]

The 1Q18 10-Q has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm

[DewDiligence]

SNDX 1Q18 results—cash=$113M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html

[DewDiligence]

SNDX ASCO lineup:

https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html

[DewDiligence]

Yes—please see my reply in #msg-140012720.

[tika1]

Dew,
Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


Oral Presentations:

Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Presenter: Anthony W. Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C - McCormick Place North (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.

[DewDiligence]

SNDX presentation lineup at AACR:

https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html

[DewDiligence]

The annual-report proxy has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000114036118018005/bp05609x1_proxy.htm

[DewDiligence]

The 2017 10-K has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/sndx-10k_20171231.htm